Pediatrix Medical Group (MD) Set to Release Quarterly Earnings on Thursday

Pediatrix Medical Group (NYSE:MD) is expected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $498.18 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The company had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.53 earnings per share. On average, analysts expect Pediatrix Medical Group to post $2.17 EPS for the current fiscal year and $2.23 EPS for the next fiscal year.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $28.98 on Tuesday. The firm has a 50-day moving average of $26.70 and a 200-day moving average of $23.72. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.32. The stock has a market cap of $2.35 billion, a PE ratio of 13.87 and a beta of 0.61. Pediatrix Medical Group has a 52-week low of $16.90 and a 52-week high of $30.05.

Analysts Set New Price Targets

Several research firms have weighed in on MD. UBS Group increased their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 13th. Jefferies Financial Group lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating and increased their target price for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. Weiss Ratings upgraded Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 9th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price target on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $26.60.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company’s clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.